Expression of p53 & epidermal growth factor receptor in glioblastoma

被引:6
|
作者
Karnam, Sameera
Kottu, Radhika [1 ]
Chowhan, Amit Kumar
Bodepati, Prasad Chandramouleswara
机构
[1] Sri Venkateswara Inst Med Sci, Dept Pathol, Alipiri Rd, Tirupati 517507, Andhra Pradesh, India
关键词
Epidermal growth factor receptor; glioblastoma; immunohistochemistry; p53; ASTROCYTOMA PROGRESSION; GENE AMPLIFICATION; MULTIFORME; MUTATIONS; PROTEIN; EGFR; HETEROZYGOSITY; CLASSIFICATION; POPULATION; PATHWAYS;
D O I
10.4103/ijmr.IJMR_1179_15
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopathologically, primary and secondary GBs are indistinguishable. The aim of this investigation was to study the immunohistochemical (IHC) expression of p53 and epidermal growth factor receptor (EGFR) in GB with the objective of categorizing the morphological variants of GB into primary and secondary based on the presence of low-grade areas and knowing the variable expression of p53 and EGFR in primary and secondary GB. Methods: A total of 28 patients with GB were studied and categorized into primary and secondary based on the presence of low-grade areas, i.e. discernible astrocytic morphology, gemistocyte and oligodendroglia. Tumours with the presence of combination of the above features or any one of the above features were taken as secondary GB, whereas tumours with highly pleomorphic areas were considered as primary GB. IHC was done on the representative tissue blocks for p53 and EGFR. Results: Majority of the patients were in the fifth and sixth decades of life with a mean age of 46.96 +/- 13 yr with male preponderance (male:female 2.5:1). Mean age of presentation was 48.93 +/- 12 yr in primary and 44.69 +/- 15 yr in secondary GB. All cases of GB were classified into primary (53.57%) and secondary (46.43%) based on morphology. EGFR was more frequently expressed than p53. Based on IHC, 50 per cent of cases were classified into primary, three per cent into secondary and 47 per cent as unclassified. Interpretation & conclusions: Histopathological features, i.e. presence of low-grade areas, may play a role in classifying GB into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary.
引用
收藏
页码:738 / 745
页数:8
相关论文
共 50 条
  • [31] Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression
    Reifenberger, J
    Ring, GU
    Gies, U
    Cobbers, JMJL
    Oberstrass, J
    An, HX
    Niederacher, D
    Wechsler, W
    Reifenberger, G
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (07): : 822 - 831
  • [32] Serum epidermal growth factor receptor and p53 as predictors of lung cancer risk in the ATBC study
    Hemminki, K
    Palmgren, J
    Korhonen, P
    Partanen, R
    Brandt-Rauf, P
    Rautalahti, M
    Albanes, D
    Virtamo, J
    [J]. BIOMARKERS, 1999, 4 (01) : 72 - 84
  • [33] Usefulness of Epidermal Growth Factor Receptor and p53 Cocktail Immunostaining for Differential Diagnosis with Urine Cytology
    Ikeda, Satoshi
    Funakoshi, Naoya
    Suzuki, Keiko
    [J]. ACTA CYTOLOGICA, 2009, 53 (01) : 29 - 35
  • [34] Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes
    A Bheda
    K E Creek
    L Pirisi
    [J]. Oncogene, 2008, 27 : 4315 - 4323
  • [35] Epidermal growth factor receptor in glioblastoma (Review)
    Xu, Hongsheng
    Zong, Hailiang
    Ma, Chong
    Ming, Xing
    Shang, Ming
    Li, Kai
    He, Xiaoguang
    Du, Hai
    Cao, Lei
    [J]. ONCOLOGY LETTERS, 2017, 14 (01) : 512 - 516
  • [36] MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
    Korkolopoulou, P
    Christodoulou, P
    Kouzelis, K
    Hadjiyannakis, M
    Priftis, A
    Stamoulis, G
    Seretis, A
    ThomasTsagli, E
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1269 - 1278
  • [37] Expression of p53, epidermal growth factor receptor, c-erbB2 in oral leukoplakias and oral squamous cell carcinomas
    Singla, Swati
    Singla, Gaurav
    Zaheer, Sufian
    Rawat, Dushyant Singh
    Mandal, Ashish Kumar
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (02) : 388 - 393
  • [38] MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor
    P Korkolopoulou
    P Christodoulou
    K Kouzelis
    M Hadjiyannakis
    A Priftis
    G Stamoulis
    A Seretis
    E Thomas-Tsagli
    [J]. British Journal of Cancer, 1997, 75 : 1269 - 1278
  • [39] p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas
    Anderson, SE
    Nonaka, D
    Chuai, S
    Olshen, AB
    Chi, D
    Sabbatini, P
    Soslow, RA
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) : 849 - 853
  • [40] EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN GLIOBLASTOMA-MULTIFORME
    PIGOTT, TJD
    ROBSON, DK
    PALMER, J
    WARD, LM
    [J]. BRITISH JOURNAL OF NEUROSURGERY, 1993, 7 (03) : 261 - 265